IN8bio (INAB) Q2 Loss Narrows 77%
IN8bio (NASDAQ:INAB), a clinical-stage biotechnology company focused on developing gamma-delta T cell therapies for cancer and autoimmune diseases, released its second quarter results on August 7, 2025. The most significant news was a sharply reduced net loss (GAAP) compared to the same quarter in the prior year and clinical progress for its lead programs, particularly in glioblastoma. IN8bio reported a loss per share of $(1.24) (GAAP). As expected for a clinical-stage biotech, no revenue was recorded. Research and development costs (GAAP) dropped steeply from the prior year, falling to $2.5 million from $5.2 million in Q2 2024, while cash on hand rose to $13.2 million. The quarter showed controlled spending and clinical milestones, yet still reflects the challenges of no operating revenue and limited funding runway.
Source: Analyst estimates for the quarter provided by FactSet.
IN8bio is developing a platform of cell therapies using gamma-delta T cells, a type of immune cell believed to help target and destroy cancer cells. Its current lead programs include INB-200 for glioblastoma (an aggressive brain tumor), INB-100 for leukemia, and preclinical work on autoimmune disorders.
Source Fool.com
